DennisNorway schreef op 25 mei 2016 22:00:
[...]
AB voor je Rabo rapport!
Twee positieve conclusies uit het rapport:
In case Phase III results of filgotinib are positive and the drug get submitted for FDA approval,
we deem it highly likely that Gilead will try to acquire Galapagos, given Gilead’s track record. Galapagos’,on the other hand, aims to become a true independent biotech company in Europe. One of the most comparable deals in our view is the acquisition of Pharmasset by Gilead, although the size of this deal
was large, compared to the current size of Galapagos. At the time Gilead acquired Pharmasset in 2011, Pharmasset had three potential hepatitis C drugs in clinical testing. Pharmasset’s lead compound, PSI-
7977 (tradename: Sovaldi), obtained FDA approval in December 2013.
The public offer was announced only weeks after Pharmasset announced the initiation of a Phase III program.Despite Gilead’s track record of acquiring 100% of other pharmaceutical companies, we do support Galapagos’ view regarding the intentions to become a biotech company instead of trying to be acquired by one of the big pharma companies.
Royalties will provide significant shareholder value while the current compounds not yet in clinical trials could provide further upside going forward.